CD19 and acute lymphoblastic leukemia: Another accelerated manufacturing platform, termed FasT CAR-T, has been used to generate “CD19 F-CAR-T” cells for patients with B-ALL, with 92% (23/25) of patients achieving minimum residual disease-negative complete responses (Yang et al., 2022).